🇺🇸 FDA

Intelligence · Clinical Pipeline

George Institute for Pipeline

All ClinicalTrials.gov programs at George Institute for — phase, modality, and trial IDs.

Programs
187

Quick answer

George Institute for has 187 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, medoxa 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery

    phase 2 small molecule active

    1 trial

  2. Levact 2,5 mg/ml, polvo para concentrado para solución para perfusión., Beneflur10 mg comprimidos recubiertos con película, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión, HSP-CAR19M

    The George Institute

    Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma

    phase 2 small molecule active

    1 trial

  3. Lidocaína B. Braun 20 mg/ml solución inyectable, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio

    The George Institute

    headache pain related to SAH, Spontaneous subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  4. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  5. Lonsurf 15 mg/6.14 mg film-coated tablets, IRINOTECAN, Bemarituzumab, PACLITAXEL, RAMUCIRUMAB

    The George Institute

    FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction

    phase 2 small molecule active

    1 trial

  6. Loratadina NORMON 10 mg Comprimidos EFG

    The George Institute

    Effect of loratadine in patients with lymphangioleiomyomatosis

    phase 2 small molecule active

    1 trial

  7. Lutathera 370 MBq/mL solution for infusion, LysaKare 25 g/25 g solution for infusion

    The George Institute

    Neuroendocrine tumor

    phase 2 small molecule active

    1 trial

  8. Lytgobi 4 mg film-coated tablets, 5-FU medac 50 mg/ml, Injektionslösung, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tevimbra 100 mg concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  9. METFORMIN , The placebo components are propylene glycol, neoPCLO/W, fenonip XB and purified water., METHYL AMINOLEVULINATE

    The George Institute

    Actinic keratoses

    phase 2 small molecule active

    1 trial

  10. Metformin Zentiva 500 mg Filmtabletten

    The George Institute

    Multidrug rezistant pulmonary tuberculosis

    phase 2 small molecule active

    1 trial

  11. OLAPARIB, BEVACIZUMAB

    The George Institute

    Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  12. OMEPRAZOLE , ACETYLSALICYLIC ACID

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  13. ONCOVIN 1 mg, solution injectable, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, ENDOXAN 1000 mg, poudre pour solution injectable, ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, TEPADINA 15 mg powder for concentrate for solution for infusion, THIOTEPA GENOPHARM 15 mg, lyophilisat pour usage parentéral

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  14. OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma

    phase 2 small molecule active

    1 trial

  15. OPDIVO 10 mg/mL concentrate for solution for infusion., Inrebic 100 mg hard capsules

    The George Institute

    Primary and secondary Myelofibrosis

    phase 2 small molecule active

    1 trial

  16. OPDIVO 10 mg/mL concentrate for solution for infusion., Regorafenib_IJB

    The George Institute

    Locally-advanced stage II-III rectal cancer

    phase 2 small molecule active

    1 trial

  17. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous

    The George Institute

    Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.

    phase 2 small molecule active

    1 trial

  18. Ogivri 150 mg powder for concentrate for solution for infusion, TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets

    The George Institute

    HER3-mutant and HER2-not amplified metastatic breast cancer

    phase 2 small molecule active

    1 trial

  19. Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib

    The George Institute

    Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma

    phase 2 small molecule active

    1 trial

  20. Omomyc

    The George Institute

    Advanced High-Grade Osteosarcoma

    phase 2 small molecule active

    1 trial

  21. Ontruzant 420 mg powder for concentrate for solution for infusion, Oxaliplatin onkovis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    HER2-positive, localized esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, 5-FU medac 50 mg/ml, Injektionslösung, DS-8201a

    The George Institute

    HER2 positive resectable esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. Ozempic 0.25 mg solution for injection in pre-filled pen, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    The George Institute

    Craving for and use of chemsex-related drugs

    phase 2 small molecule active

    1 trial

  24. PACLITAXEL, Durvalumab_IJB, CARBOPLATIN, Oleclumab_IJB

    The George Institute

    Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

    phase 2 small molecule active

    1 trial

  25. PACLITAXEL, MaaT033, CISPLATIN, CARBOPLATIN, GEMCITABINE, PACLITAXEL, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, GEMCITABINE, PEMETREXED, BEVACIZUMAB, PACLITAXEL, DOCETAXEL, PEMETREXED, DOCETAXEL, BEVACIZUMAB, GEMCITABINE, CISPLATIN, VINORELBINE, PACLITAXEL, CARBOPLATIN, VINORELBINE, CARBOPLATIN, VINORELBINE, PEMETREXED, VINORELBINE, DOCETAXEL, GEMCITABINE, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, PEMETREXED, PEMETREXED, CISPLATIN, PEMETREXED, DOCETAXEL

    The George Institute

    Advanced non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  26. PEMBROLIZUMAB, OLAPARIB, OLAPARIB

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  27. PIROXICAM, LIDOCAINE HYDROCHLORIDE

    The George Institute

    lateral epicondylitis

    phase 2 small molecule active

    1 trial

  28. PRAVASTATIN

    The George Institute

    Patients with severe and radio-induced breast fibrosis after breast cancer

    phase 2 small molecule active

    1 trial

  29. Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  30. Padcev 30 mg powder for concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion

    The George Institute

    locally advanced or metastatic penile squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  31. Pemazyre 4.5 mg tablets

    The George Institute

    locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements

    phase 2 small molecule active

    1 trial

  32. Pentasa Sachet 2 g depotgranulat, Pentasa PLACEBO Sachet 2g in the granule formulation specifically designed to resemble the active drug product

    The George Institute

    Lynch syndrome, which is increasing the risk of developing colorectal cancer

    phase 2 small molecule active

    1 trial

  33. Perjeta 420 mg concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    The George Institute

    Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  34. Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  35. Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

    The George Institute

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  36. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  37. Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma

    The George Institute

    Malignant Peritoneal Mesothelioma

    phase 2 other active

    1 trial

  38. Pimavanserina 34 mg placebo cápsulas, Pimavanserin tartrate

    The George Institute

    Major depressive disorder

    phase 2 small molecule active

    1 trial

  39. Placebo tablets are produced with the same appearance as the Valganciclovir tablets, with the same content except for the active compound., VALGANCICLOVIR

    The George Institute

    Glioblstoma WHO grade IV

    phase 2 small molecule active

    1 trial

  40. Plasma rich in growth factors

    The George Institute

    Low Reserve Ovarian

    phase 2 small molecule active

    1 trial

  41. Posaconazol STADA 100 mg magensaftresistente Tabletten, S65487 Solution for infusion 100 mg, Vidaza 25 mg/ml powder for suspension for injection

    The George Institute

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  42. Powder for concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets, Zyloric 300 mg Tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Zyloric 100 mg Tablet

    The George Institute

    "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"

    phase 2 small molecule active

    1 trial

  43. Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors

    The George Institute

    Pancreatic well differentiated neuroendocrine tumors (NET)

    phase 2 other active

    1 trial

  44. Retifanlimab (INCMGA00012), HOLOXAN 2000 mg, poudre pour usage parentéral, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  45. Rifampicin 150 mg Capsules, RIMSTAR®, COMPRIMIDOS RECUBIERTOS CON PELÍCULA, Rifampicin 300 mg Capsules

    The George Institute

    TUBERCULOSIS

    phase 2 small molecule active

    1 trial

  46. Rimactan 300 mg hörð hylki., Moxifloxacin Tillomed 400 mg film coated tablets, LINEZOLID, RIMSTAR®, COMPRIMIDOS RECUBIERTOS CON PELÍCULA, Hidroxil B1-B6-B12 comprimidos recubiertos con película, Zyvoxid 600 mg Filmtabletten

    The George Institute

    Bacilliferous pulmonary tuberculosis

    phase 2 small molecule active

    1 trial

  47. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  48. S230815 Solution for injection 10mg/ml

    The George Institute

    KCNT1-related Developmental and Epileptic Encephalopathy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does George Institute for have?

187 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.